By Frank Prenesti
Date: Monday 27 Jan 2020
(Sharecast News) - AstraZeneca said it had agreed to sell the global commercial rights to a range of hypertension treatments to Atnahs Pharma for up to $390m.
Abbvie boss blasts US tax regime | 21-Oct-2014 | Telegraph |
Drug company AbbVie takeover rival in £31bn bid | 18-Jul-2014 | Express & Star |
AbbVie to announce firm bid for Shire | 18-Jul-2014 | Telegraph |
AbbVie's raised proposal for Shire gets board ba... | 15-Jul-2014 | Guardian |
Shire set to accept £31bn bid from US rival AbbVie | 15-Jul-2014 | Express & Star |
No recent information was found.
No recent information was found.
Currency | US Dollars |
Share Price | $ 210.60 |
Change Today | $ 1.10 |
% Change | 0.53 % |
52 Week High | $216.66 |
52 Week Low | $164.99 |
Volume | 5,516,870 |
Shares Issued | 1,765.26m |
Market Cap | $371,763m |
RiskGrade | 122 |
Strong Buy | 7 |
Buy | 13 |
Neutral | 9 |
Sell | 0 |
Strong Sell | 0 |
Total | 29 |
Time | Volume / Share Price |
15:59 | 136 @ $210.60 |
15:59 | 100 @ $210.61 |
15:59 | 126 @ $210.60 |
15:59 | 127 @ $210.60 |
15:59 | 100 @ $210.61 |
You are here: research